Leerink Partnrs Has Pessimistic View of Vaxcyte Q3 Earnings

Key Points

• Leerink Partners has lowered its Q3 2025 earnings per share estimate for Vaxcyte to ($1.47), down from a previous estimate of ($1.22).
• Vaxcyte recently reported a Q2 loss of ($1.22) EPS, missing analysts' expectations of ($1.12) EPS by $0.10.
• Vaxcyte's stock currently has an average rating of "Buy" with a consensus price target of $136.50 from multiple analysts.

Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) - Research analysts at Leerink Partnrs lowered their Q3 2025 earnings estimates for Vaxcyte in a research report issued to clients and investors on Thursday, August 7th. Leerink Partnrs analyst D. Risinger now anticipates that the company will post earnings per share of ($1.47) for the quarter, down from their prior forecast of ($1.22). The consensus estimate for Vaxcyte's current full-year earnings is ($4.21) per share. Leerink Partnrs also issued estimates for Vaxcyte's Q4 2025 earnings at ($1.50) EPS, FY2025 earnings at ($5.96) EPS, FY2026 earnings at ($6.58) EPS, FY2027 earnings at ($7.07) EPS, FY2028 earnings at ($6.87) EPS and FY2029 earnings at ($1.69) EPS.

PCVX has been the topic of a number of other research reports. Cantor Fitzgerald began coverage on shares of Vaxcyte in a report on Tuesday, April 22nd. They set an "overweight" rating on the stock. Cowen reissued a "buy" rating on shares of Vaxcyte in a research note on Thursday, August 7th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and an average target price of $136.50.

Vaxcyte Stock Performance

Shares of NASDAQ:PCVX traded down $0.01 during mid-day trading on Monday, reaching $31.54. 422,155 shares of the company's stock were exchanged, compared to its average volume of 1,786,168. The firm has a market capitalization of $4.09 billion, a price-to-earnings ratio of -7.66 and a beta of 1.21. The business's fifty day moving average price is $34.18 and its 200-day moving average price is $47.48. Vaxcyte has a twelve month low of $27.66 and a twelve month high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($1.22) EPS for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.10). During the same period in the prior year, the business posted ($1.10) EPS.

Institutional Investors Weigh In On Vaxcyte

Hedge funds and other institutional investors have recently bought and sold shares of the stock. National Bank of Canada FI purchased a new position in Vaxcyte during the fourth quarter worth about $41,000. Wells Fargo & Company MN increased its holdings in Vaxcyte by 53.7% during the 4th quarter. Wells Fargo & Company MN now owns 72,275 shares of the company's stock worth $5,916,000 after acquiring an additional 25,257 shares during the period. Envestnet Asset Management Inc. increased its holdings in Vaxcyte by 12.5% during the 4th quarter. Envestnet Asset Management Inc. now owns 55,083 shares of the company's stock worth $4,509,000 after acquiring an additional 6,121 shares during the period. Legal & General Group Plc increased its holdings in Vaxcyte by 13.4% during the 4th quarter. Legal & General Group Plc now owns 123,664 shares of the company's stock worth $10,123,000 after acquiring an additional 14,574 shares during the period. Finally, Renaissance Technologies LLC bought a new position in shares of Vaxcyte in the 4th quarter worth $4,427,000. 96.78% of the stock is owned by institutional investors.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.